Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04125290 · ClinicalTrials.gov registry record
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04125290: Clinical Trial study, sponsored by AstraZeneca.
NCT04125290 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04125290 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of moxetumomab pasudotox-tdfk in patients who have moderate renal impairment defined as an estimated GFR of 30-59 ml/min
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2021-06-21 |
Why NCT04125290 stopped before completion
NCT04125290 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04125290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04125290 about?
NCT04125290 is a clinical study titled "US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)". This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of moxetumomab pasudotox-tdfk in patients who have moderate renal impairment d...
What is the current status of trial NCT04125290?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-12-09. Estimated completion is 2021-06-21.
Who is sponsoring clinical trial NCT04125290?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI